Search results for "prostate"

showing 10 items of 621 documents

Comparison of RNA-seq and microarray-based models for clinical endpoint prediction

2015

Background Gene expression profiling is being widely applied in cancer research to identify biomarkers for clinical endpoint prediction. Since RNA-seq provides a powerful tool for transcriptome-based applications beyond the limitations of microarrays, we sought to systematically evaluate the performance of RNA-seq-based and microarray-based classifiers in this MAQC-III/SEQC study for clinical endpoint prediction using neuroblastoma as a model. Results We generate gene expression profiles from 498 primary neuroblastomas using both RNA-seq and 44 k microarrays. Characterization of the neuroblastoma transcriptome by RNA-seq reveals that more than 48,000 genes and 200,000 transcripts are being …

AdultMaleMicroarrayAdolescentEndpoint DeterminationNEUROBLASTOMA PATIENTSgenetic processesRNA-SeqBiologyBioinformaticsRISK STRATIFICATIONTranscriptomeNeuroblastomaYoung AdultREPRODUCIBILITYClinical endpointTumor Cells CulturedBREAST-CANCERHumansnatural sciencesTRANSCRIPTOMEChildGENE-EXPRESSIONOligonucleotide Array Sequence AnalysisSettore BIO/11 - BIOLOGIA MOLECOLAREEXPRESSION-BASED CLASSIFICATIONModels GeneticSequence Analysis RNAGene Expression ProfilingResearchSIGNATUREInfant NewbornBiology and Life SciencesInfantHuman genetics3. Good healthPROSTATE-CANCERGene expression profilingDIFFERENTIATIONChild PreschoolEndpoint DeterminationFemaleDNA microarray
researchProduct

Optimal local control and tolerability of three-dimensional conformal radiation therapy in prostate cancer: A single institutional experience of dose…

2013

Aims To evaluate long-term late side effects, clinical and biochemical relapse in non-metastatic prostate cancer patients treated with dose escalation, from 74 to 78 Gy, by means of three dimensional conformal radiation therapy. Materials and Methods Clinical data of 125 patients with prostate cancer who underwent three-dimensional conformal radiation therapy were retrospectively evaluated. All patients were stratified, according to the NCCN classification, in low, intermediate and high risk, and all of them showed histologically proven adenocarcinoma stage T1–T3 with at least 2 years of follow-up. Late toxicity was analyzed using a modified Radiation Therapy Oncology Group toxicity scale. …

MaleCancer ResearchThree dimensional conformal radiation therapyUrinary BladderUrogenital SystemKaplan-Meier EstimateAdenocarcinomaDisease-Free SurvivalBiomarkers Tumor80 and overHumansLate toxicity; Local control; Prostate cancer; Radiation therapy; Three dimensional conformal radiation therapy; Adenocarcinoma; Aged; Aged 80 and over; Biomarkers Tumor; Disease-Free Survival; Gastrointestinal Tract; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Conformal; Rectum; Retrospective Studies; Urinary Bladder; Urogenital System; Medicine (all); Oncology; Cancer ResearchRadiation InjuriesAgedNeoplasm StagingRetrospective StudiesAged 80 and overProstate cancerTumorRadiotherapyConformalMedicine (all)RectumProstatic NeoplasmsRadiotherapy DosageGeneral MedicineMiddle AgedProstate-Specific AntigenRadiation therapyGastrointestinal TractItalyOncologyLocal controlRadiotherapy ConformalLate toxicityBiomarkers
researchProduct

Prostatectomia radicale mini laparoscopica: note di tecnica e risultati comparativi

2014

mini laparoscopiaprostatectomiaSettore MED/24 - Urologia
researchProduct

Distinct Osteomimetic Response of Androgen-Dependent and Independent Human Prostate Cancer Cells to Mechanical Action of Fluid Flow: Prometastatic Im…

2016

BACKGROUND AND METHODS Prostate cancer frequently expresses an osteomimetic phenotype, but it is unclear how it is regulated and what biological and clinical implications it confers. Because mechanical forces physiologically regulate bone-remodeling activity in osteocytes, we hypothesized that mechanical action of fluid flow (MAFF) at the cancer microenvironment may similarly foster prostate cancer cell osteomimicry. RESULTS We showed that in vitro MAFF on androgen-dependent (LNCap) and androgen-independent (PC3) prostate cancer cells remarkably increased OPG, VEGF, RunX2, PTH1R, and PTHrP gene expression in both cell lines irrespective of their androgen dependency. MAFF also altered the cy…

0301 basic medicinemedicine.medical_specialtyAngiogenesisUrologymedicine.medical_treatmentBiologyurologic and male genital diseasesmedicine.diseaseMetastasis03 medical and health sciencesProstate cancer030104 developmental biology0302 clinical medicineEndocrinologyCytokineOncology030220 oncology & carcinogenesisInternal medicineCancer cellLNCaPmedicineCancer researchCytokine secretionTumor necrosis factor alphaThe Prostate
researchProduct

Primary Mucinous Adenocarcinoma of the Urinary Bladder with Signet-Ring Cells: Description of an Uncommon Case and Critical Points in Its Management

2016

We present an uncommon case of mucinous adenocarcinoma of the bladder (MAB) with signet-ring cells extensively infiltrating prostate gland and pelvic/retroperitoneal lymph node stations and not responsive to usual systemic chemotherapy regimens. This case highlights the important features of MAB including the pattern of tumor spread, the tendency for initial misdiagnosis, and the importance of immunohistochemical study in order to define its primary origin from the bladder and choose the most appropriate treatment since the beginning.

Pathologymedicine.medical_specialtyUrinary bladderSignet ring cellSystemic chemotherapybusiness.industryRetroperitoneal Lymph Node030232 urology & nephrologyCase ReportGeneral Medicinemedicine.diseaselcsh:Diseases of the genitourinary system. Urologylcsh:RC870-92303 medical and health sciences0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesismedicineAdenocarcinomaImmunohistochemistryProstate glandbusinessCase Reports in Urology
researchProduct

Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells

2013

International audience; The proapoptotic protein, prostate apoptosis response-4 (Par-4), acts as a tumor suppressor in prostate cancer cells. The serine/threonine kinase casein kinase 2 (CK2) has a well-reported role in prostate cancer resistance to apoptotic agents or anticancer drugs. However, the mechanistic understanding on how CK2 supports survival is far from complete. In this work, we demonstrate both in rat and humans that (i) Par-4 is a new substrate of the survival kinase CK2 and (ii) phosphorylation by CK2 impairs Par-4 proapoptotic functions. We also unravel different levels of CK2-dependent regulation of Par-4 between species. In rats, the phosphorylation by CK2 at the major si…

MaleCancer Researchanimal structuresCK2[SDV]Life Sciences [q-bio]ImmunologyAmino Acid MotifsPAWR[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC]Biology[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biology[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and NephrologyCellular and Molecular NeuroscienceProstate cancer[SDV.CAN] Life Sciences [q-bio]/CancerProstateCell Line Tumor[SDV.BC.BC] Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC]medicineAnimalsHumansCasein Kinase IIComputingMilieux_MISCELLANEOUSGene knockdownKinasephosphorylationfungita1182apoptosisProstatic Neoplasms[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyCell Biologymedicine.diseaseprostate cancer[SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and NephrologyRatsmedicine.anatomical_structureApoptosisembryonic structuresCancer researchPhosphorylationOriginal ArticleCasein kinase 2Apoptosis Regulatory ProteinsPar-4
researchProduct

Interleukin-6 and Lymphocyte Count Associated and Predicted the Progression of Frailty Syndrome in Prostate Cancer Patients Undergoing Antiandrogen T…

2020

Frailty syndrome is a functional state that includes a loss of ability to react to stressors, and is associated with poor outcomes, morbidity and premature mortality. The first line treatment in many men with prostate cancer (PCa) consists of an androgen-deprivation therapy (ADT) which can promote or favor frailty syndrome and ADT may therefore favor the progression of frailty over time. Among the pathophysiological bases of frailty, the presence of chronic low-grade inflammation has been associated with its adverse outcomes, but longitudinal studies are needed to validate these biomarkers. In this study, we prospectively evaluate frailty syndrome and blood inflammatory markers (IL1-beta, I…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyleukocytesgeriatric assessmentLymphocyteFrailty syndromeInflammationinterleukin-1 betalcsh:RC254-282Article03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinemedicineInterleukin 6Receiver operating characteristicbiologybusiness.industryinterleukin-6C-reactive proteinlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologymedicine.anatomical_structureOncologyinflammation030220 oncology & carcinogenesisbiology.proteinBiomarker (medicine)biomarkermedicine.symptombusinessCancers
researchProduct

Defining new biotypes in Prostate Cancer for diagnosis, prognosis and therapeutic intervention

2015

El cáncer de próstata (CaP) es el segundo tumor más frecuente en hombres y la sexta causa de muerte por cáncer. Así pues, esta enfermedad constituye un problema socio-sanitario prioritario para el sistema de Salud Pública. Actualmente, las herramientas para orientar el diagnóstico en CaP (PSA y DRE) no son cáncer específicas y presentan distintas limitaciones tales como el alto número de falsos positivos (aproximadamente un 70% en un rango de PSA de 4-10 ng/ml) que dan lugar a complicaciones asociadas con el proceso de biopsia. Además, un gran número de los CaP diagnosticados son tumores de bajo grado implicando un sobre-diagnóstico y sobre-tratamiento de esta enfermedad. Sin embargo, otros…

diagnosisUNESCO::CIENCIAS DE LA VIDAbiomarkerpersonalized medicineprognosisprostate cancer:CIENCIAS DE LA VIDA [UNESCO]
researchProduct

Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned

2016

Nine out of ten metastatic prostate cancer (PCa) patients will develop osseous metastases. Of these, every second will suffer from skeletal-related events (SRE). SRE are associated with an increased risk for death, which is markedly increased in the presence of pathological fracture. Moreover, health insurance costs nearly double in the presence of SRE. Zoledronic acid and denosumab are both approved drugs for the prevention or delay of SRE in castration-resistant prostate cancer (CRPC) patients with osseous metastases. However, long-term treatment with one of these two drugs is associated with the development of medication-related osteonecrosis of the jaw (MRONJ). Routine inspections of th…

Oncologymedicine.medical_specialtyReview03 medical and health sciencesProstate cancerzoledronic acid0302 clinical medicineInternal medicinemedicineStage (cooking)General DentistryPathologicalmedicine.diagnostic_testbusiness.industryIncidence (epidemiology)osteonecrosisdenosumab030206 dentistrymedicine.diseaseprostate cancerSurgerylcsh:RK1-715Zoledronic acidDenosumabBone scintigraphy030220 oncology & carcinogenesislcsh:DentistrybusinessOsteonecrosis of the jawmedicine.drugDentistry Journal
researchProduct

Does Exist A Correlation Between BMI and Gleason Patterns 4 and 5 At Prostate Biopsy?

2013

Background: Obesity has been related with higher Gleason grade and worse prognosis. Increasing proportion of Gleason pattern 4 or 5 is a critical factor for biochemical recurrence, progression and mortality. The endocrine activity of visceral fat could be responsible of the differentation of the prostatic malignant cell towards a more aggressive fenotype. The aim of our study was to correlate Body Mass Index with the presence of Gleason pattern 4 or higher at biopsy. Materials and Methods: Consecutive patients with positive prostate biopsy were included. A transrectal prostate biopsy procedure with 12 cores, was performed. All tissue samples were reviewed. Results: Out of 135 patients diagn…

Gleason gradeOncologyBiochemical recurrencemedicine.medical_specialtyProstate cancerProstate biopsymedicine.diagnostic_testbusiness.industryUrologyurologic and male genital diseasesGleason grademedicine.diseaseSettore MED/24 - UrologiaCorrelationBMIProstate cancerProstate BiopsyInternal medicineBiopsymedicineMalignant cellsObesitybusinessBody mass indexJournal of Cytology & Histology
researchProduct